

Simple and Efficient Synthesis of New Chiral *N,N'*-Sulfonyl Bis-Oxazolidin-2-Ones

Malika Berredjem,¹ Zine Regainia,¹ Georges Dewynter,²
Jean Louis Montero,³ and Nour-Eddine Aouf¹

¹Laboratoire de Chimie Organique Appliquée, Groupe de Chimie Bioorganique, Université d'Annaba, BP12, Algérie

²UMR 5810 Laboratoire des Aminoacides, Peptides et Protéines CC 019, Universités Montpellier-I et II, place E. Bataillon, 34095 Montpellier cedex 5, France

³UMR 5032 Laboratoire de Chimie Biomoléculaire, Universités Montpellier II, ENSCM, 8 rue de l'Ecole Normale, 34096 Montpellier cedex, France

Received 14 October 2005; revised 18 October 2005

ABSTRACT: A series of new chiral *N,N'*-sulfonyl bis-oxazolidin-2-ones were synthesized starting from 2-aminoalcohols, sulfonyl chloride, and diethyl carbonate. This method utilizes natural amino acids as a source of chirality for the preparation of oxazolidinones. © 2006 Wiley Periodicals, Inc. *Heteroatom Chem* 17:61–65, 2006; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.20183

INTRODUCTION

Chiral oxazolidin-2-ones have emerged as a very important class of compounds in drug development especially in the area of antimicrobials [1–6], and they have been utilized as auxiliaries for a wide range of asymmetric transformations (Evans oxazolidinones) [7–11]. They are also found as a precursor in the synthesis of a variety of heterocyclic compounds, as a

protecting group in organic synthesis, as ligands for metal catalysts, and as biologically active pharmaceutical agents [12–15]. In spite of these facts, very few reports in the literature have reported the synthesis and the use of *N*-sulfonyl oxazolidin-2-ones and bis-sulfonyl oxazolidin-2-one.

Previously, Dewynter et al. reported the synthesis of sulfonyl bis-oxazolidin-2-one **2** for development of soft crosslinking and reticulation reagent for bionucleophiles [16]. Lee et al. described the synthesis of the first hydrosoluble C-2 symmetric bis(oxazolidinone) [17] **1** as a potential bifunctional chiral auxiliary via regioselective intramolecular cyclization of the bis(carbamate). Due to our interest in the reactivity of *N*-sulfonyl oxazolidin-2-ones, we attempted their conversion to chiral bis *N,N'*-sulfonyl bis-oxazolidin-2-ones **3**.

Recently, we have reported the synthesis and the reactivity of the *N*-chlorosulfonyl oxazolidin-2-ones toward aminoesters [17]. In this paper, we have extended our studies in the chiral *N,N'*-sulfonyl bis-oxazolidin-2-ones C₂-symmetric and unsymmetric, in which both heterocyclic carbonyl groups can serve as electrophilic centers. Relating to structural filiation, these compounds can be considered as chiral *sulfa*-analogues of carbonyl and phosphoryl reagents such as carbonyldimidazole (CDI) and bis-oxazolidin-2-one phosphoryl chloride (BOP-Cl) [18].

To Dr Kamel Seghoum, *in memoriam*.
Correspondence to: Nour-Eddine Aouf; e-mail: noureddineaouf@yahoo.fr

Contract grant sponsor: Algerian Research Ministry.
Contract grant sponsor: National Agency for the Development of Research in Health.

Contract grant number: ANDRS, project no. 5/05/00039 and CNEPRU project E 2301/02/04.

© 2006 Wiley Periodicals, Inc.





FIGURE 1

CHEMISTRY


The purpose of using amino acids was to introduce the chirality in the target molecules. The reaction between amino alcohols and diethyl carbonate has proved to yield a direct route to oxazolidinones. The chiral oxazolidinon-2-ones can be prepared in two steps starting from the corresponding amino acids (Ala, Val, Leu, Phe), reduction with sodium borohydride, and cyclization using diethyl carbonate [19]. Sulfonyl chloride was used to introduce the chlorosulfonyl and sulfonyl moieties on oxazolidinone and bis-*N*-sulfonyloxazolidinon-2-ones (SBO).

Alternatively, SBO can be synthesized directly starting from sulfonyl chloride and oxazolidin-2-one, or in two steps by formation of *N*-chlorosulfonyloxazolidin-2-ones (CSO) as an intermediate.

The route to the C_2 -symmetric and unsymmetric SBO **2a-e**, **3** is outlined in Scheme 1. Different chiral chlorosulfonyloxazolidin-2-ones **1a-e** have been synthesized starting from sulfonyl chloride, and chi-



SCHEME 1




SCHEME 2

ral oxazolidin-2-one by substitution in the presence of triethylamine in dichloromethane at 0°C under anhydrous argon atmosphere produces CSO in satisfactory yields.

CSO **1** can be coupled with oxazolidin-2-one in anhydrous methylene chloride in the presence of TEA at -78°C to yield C_2 -symmetric **2a-e** and unsymmetric **3** *N,N'*-sulfonyl bis oxazolidin-2-ones (SBO) in acceptable yield.

The symmetric *N,N'*-sulfonyl bis-oxazolidin-2-ones have been synthesized using sulfonyl chloride directly, starting from corresponding commercially available or easy accessible chiral oxazolidin-2-ones (Scheme 2). Starting materials were treated at -78°C with 1 eq. of sulfonyl chloride for 1 h leading to the title compounds in satisfactory yields.

The structure of all compounds was unambiguously confirmed by usual spectroscopic methods. For resulting compounds **2a-e**, IR spectra showed bands at $1782\text{--}1800\text{ cm}^{-1}$ (C=O), suggesting its strong electrophilic ability. Characteristic bands for the sulfonyl group appear at $1110\text{--}1170\text{ cm}^{-1}$ and $1350\text{--}1185\text{ cm}^{-1}$. ^1H NMR spectra of the resulting compounds showed *dd* and multiplet system due to the diastereotopic methylene protons of oxazolidin-2-one heterocycle.



As revealed by X-Ray crystallographic analysis [16], each heterocyclic moiety and S=O group shows selective antiperiplanar orientation, which enhances values of α_D for the chiral C_2 -dimeric forms **2a-e**. SBO could be considered as a rigid skeleton grafted with substituents allowing structural and stereochemical diversity.

In conclusion, we have established a strategy described herein as effective method for the synthesis of a new variety of symmetric and unsymmetric SBO. Work is currently in progress to evaluate the reactivity of the chiral (SBO) to the primary or

secondary amines and the linkage and the reticulation of biomolecules, especially proteins. These compounds are currently being evaluated for biological activity, and the results of these investigations will be reported in due course.

EXPERIMENTAL

All commercial chemicals and solvents were used as received. All reactions were carried out under an inert atmosphere of argon. TLC analyses were performed on silica gel 60 F₂₅₄ plates (Merck Art.1.05554). Spots were visualized under 254 nm UV illumination, or by ninhydrin solution spraying. Melting points were determined on a Büchi melting point 510 and are uncorrected. Infrared spectra were recorded on a Perkin–Elmer FT–IR spectrometer S1000. ¹H and ¹³C NMR spectra were determined with a AC-250 Bruker spectrometer. For ¹H-NMR spectra, chemical shifts are expressed in δ (ppm) downfield from tetramethylsilane, and coupling constants (*J*) are expressed in Hertz. Electron ionization mass spectra (30 eV) were recorded in positive or negative mode on a Water MicroMass ZQ. High-resolution mass spectra were measured on a Jeol SX102 mass spectrometer and recorded in FAB positive mode.

General Procedure

Synthesis of N-chlorosulfonyloxazolidin-2-ones. To a solution of oxazolidin-ones **1–5** (10 mmol, 1 eq.) and triethylamine (0.670 mL, 0.486 g, 12 mmol, 1.2 eq.) in 20 mL, anhydrous methylene chloride in the presence of a catalytic quantity of dimethylamino pyridine (DMAP) at 0°C was added dropwise a solution of sulfuryl chloride (10 mmol, 1.350 g, 0.833 mL) in the same solvent (10 mL). The reaction was stirred under argon at 0°C for less than 1 h. The solvent was concentrated to 20 mL under reduced pressure, and the solution was washed with HCl 0.1 N and water. The organic layer was dried over anhydrous magnesium sulfate and concentrated in vacuo. Recrystallization from the crude product in CHCl₃–hexane 1/5 or flash chromatography (CH₂Cl₂) afforded chlorosulfonyl oxazolidin-2-one **1a–e** in 67–80% yields.

N-chlorosulfonyl-oxazolidin-2-one 1a. Yield: 75%; mp 89–90°C. *R*_f 0.65 (CH₂Cl₂: MeOH 95:5). ¹H NMR (CDCl₃, δ): 4.20 (t, 2H, *J* = 6.6 Hz), 4.50 (t, 2H, *J* = 6.6 Hz). ¹³C NMR (CDCl₃, δ): 150, 63, 46. IR (KBr): 1800, 1405, 1188 cm⁻¹; MS ESI⁺ 30 eV *m/z*: 208 [M + Na]⁺. HRMS [calcd. for C₃H₄ClNO₄S + H⁺: *m/z* [M + H]⁺ (185.9628): found 185.9623.

(S)-4-Methyl-N-chlorosulfonyl-oxazolidin-2-one 1b. Yield: 79%; mp 47–48°C. *R*_f 0.70 (CH₂Cl₂: MeOH

95:5). [α]_D = -12.1 (*c* = 1, CH₂Cl₂). ¹H NMR (CDCl₃, δ): 4.6 (m, 2H), 4.10 (m, 2H), 1.60 (d, *J* = 6.1 Hz, 3H). ¹³C NMR (CDCl₃, δ): 150, 70, 56, 19. IR (KBr): 1785, 1385, 1175 cm⁻¹; MS ESI⁺ 30 eV *m/z*: 222 [M + Na]⁺. HRMS calcd for C₄H₆ClNO₄S + H⁺: *m/z* [M + H]⁺ 199.9784, found 199.9779.

(S)-4-Isopropyl-N-chlorosulfonyl-oxazolidin-2-one 1c. Yield: 88%; mp 42–43°C. *R*_f = 0.68 (CH₂Cl₂: MeOH 95:5). [α]_D = +3.5 (*c* = 1, CH₂Cl₂). ¹H NMR (CDCl₃, δ): 4.20–4.40 (m, 2H); 2.50 (m, 1H); 1.00 (2d, *J* = 9.0 Hz, 6H). ¹³C NMR (CDCl₃, δ): 150, 64, 63, 29, 18, 14. IR (KBr): 1790, 1400, 1188 cm⁻¹. MS ESI⁺ 30 eV *m/z*: 250 [M + Na]⁺. HRMS calcd for C₆H₁₀ClNO₄S + H⁺: *m/z* [M + H]⁺ 228.0097, found 228.0092.

(S)-4-Isobutyl-N-chlorosulfonyl-oxazolidin-2-one 1d. Yield: 82%; mp 38–39°C. *R*_f = 0.64 (CH₂Cl₂: MeOH 95:5). [α]_D = +7.4 (*c* = 1, CH₂Cl₂). ¹H NMR (CDCl₃, δ): 4.40 (m, 2H), 4.20 (m, 2H), 2.10 (m, 1H), 1.70 (m, 2H), 1.00 (2d, *J* = 9.0 Hz, 6H). ¹³C NMR (CDCl₃, δ): 150, 68, 58, 41, 24, 23, 21. IR (KBr): 1793, 1415, 1191 cm⁻¹. MS ESI⁺ 30 eV *m/z*: 264 [M + Na]⁺. HRMS calcd for C₇H₁₂ClNO₄S + H⁺: *m/z* [M + H]⁺ 242.0254, found 242.0249.

(S)-4-Benzyl-N-chlorosulfonyl-oxazolidin-2-one 1e. Yield: 85%; mp 80–81°C; *R*_f = 0.74 (CH₂Cl₂: MeOH 95:5). [α]_D = -6.5 (*c* = 1, CH₂Cl₂); ¹H NMR (CDCl₃, δ): 7.20–7.42 (m, 5H), 4.70 (m, 1H), 4.30 (m, 2H), 3.60 (dd, *J* = 13.4 Hz, *J* = 3 Hz, 1H), 3.05 (dd, *J* = 13.4 Hz, *J* = 10.0 Hz, 1H). ¹³C NMR (CDCl₃, δ): 150, 134, 130, 128, 67, 60, 38. IR (KBr): 1780, 1395, 1170 cm⁻¹. MS ESI⁺ 30 eV *m/z*: 298 [M + Na]⁺. HRMS calcd for C₁₀H₁₀ClNO₄S + H⁺: *m/z* [M + H]⁺ 276.0097, found 276.0092.

Preparation of Symmetric *N,N'*-sulfonyl bis-oxazolidin-2-ones (2a–e): Procedure 1

Oxazolidin-2-one (2 eq.) in anhydrous CH₂Cl₂ (20 mL) was added sequentially to a 100-mL round bottom flask fitted with argon balloon. The solution was cooled to -78°C; triethylamine (2.78 mL, 2.02 g, 22 mmol, 2.2 eq.) and catalytic quantity of DMAP added slowly, and the resulting solution was stirred for 30 min. A solution of sulfuryl chloride in the same solvent (0.83 mL, 1.35 g, 10 mmol, 1 eq.) was added slowly over 1 h, and the resulting yellow solution was stirred for 3 h. The reaction mixture was washed with HCl 0.1 N and water. The organic layer is dried over magnesium sulfate, concentrated and separated by chromatography on silica gel (eluted with CH₂Cl₂/CH₂OH 9.5: 0.5) to afford bis-*N,N'*-sulfonyl bis-oxazolin-2-one as white solid in acceptable yields.

Preparation of Symmetric and Unsymmetric N,N'-sulfonyl Oxazolidin-2-ones (2a–e, 3): Procedure 2

Coupling of Chlorosulfonyl Oxazolidin-2-ones with Oxazolidin-2-ones. To a stirred solution of oxazolidin-2-one (1 eq., 5 mmol) in anhydrous CH₂Cl₂ (20 mL) in the presence of triethylamine (1.2 eq., 6 mmol, 0.60 g, 0.82 mL) and catalytic amount of (DMAP) at -78°C was added chlorosulfonyl oxazolidin-2-one (5 mmol, 1 eq.) in the same solvent (15 mL). The reaction mixture was stirred for 3 h at -78°C under argon. The reaction was monitored by TLC. The resulting reaction solution was allowed to warm up to room temperature for 1 h. The reaction mixture was diluted with 20 mL of methylene chloride and washed with HCl 0.1 N and water. The organic layer is dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluted with CH₂Cl₂/EP 9:1) to afford of *N,N'*sulfonyl bis-oxazolidin-2-one as white solid in good yields.

N,N'-Sulfonyl bis-oxazolidin-2-one **2a**. Yield: 70%; mp 235–238°C. $R_f = 0.62$ (CH₂Cl₂: MeOH 95:5). ¹H NMR (CDCl₃, δ): 4.65 (t, $J = 7.7$ Hz, 2H); 4.15 (t, $J = 7.7$ Hz, 2H). ¹³C NMR (CDCl₃, δ): 149.2, 63.5, 46.5. IR (KBr, ν): 1800, 1405, 1188 cm⁻¹. MS ESI⁺ 30 eV m/z : 259 [M + Na]⁺. HRMS calcd for C₆H₈N₂O₆S + H⁺: m/z [M + H]⁺ 237.0314, found 237.0313.

N,N'-Sulfonyl-bis-[(4*S*)-methyl-oxazolidin-2-one] **2b**. Yield: 80%; mp 108–110°C. $R_f = 0.75$ (CH₂Cl₂: MeOH 95:5). $[\alpha]_D = -144$ ($c = 1$, CH₂Cl₂). ¹H NMR (CDCl₃, δ): 4.72–4.60 (2dd, $J = 11.2, 7.4, 4.3$ Hz, 4H), 4.12 (m, 2H), 1.65 (d, $J = 6.1$ Hz, 3H). ¹³C NMR (CDCl₃, δ): 150.3, 71.2, 56.4, 18.5. IR (KBr, ν): 1795, 1375, 1185 cm⁻¹; MS ESI⁺ 30 eV m/z : 287 [M + Na]⁺. HRMS calcd for C₈H₁₂N₂O₆S + H⁺: m/z [M + H]⁺ 264.9784, found 264.9779.

N,N'-Sulfonyl-bis-[(4*S*)-isopropyl-oxazolidin-2-one] **2c**. Yield: 76%; mp 120–122°C; $R_f = 0.71$ (CH₂Cl₂: MeOH 95:5). $[\alpha]_D = +32.5$ ($c = 1$, CH₂Cl₂). ¹H NMR (CDCl₃, δ): 4.50 (m, 4H), 4.25 (m, 2H), 2.25 (m, 2H), 0.95 (2d, $J = 9.1$ Hz, 12 H). ¹³C NMR (CDCl₃, δ): 151.2, 63.2, 60.1, 30.1, 18.6, 14.5. IR (KBr, ν): 1795, 1485, 1185 cm⁻¹. MS ESI⁺ 30 eV m/z : 343 [M + Na]⁺. HRMS calcd for C₁₂H₂₀N₂O₆S + H⁺: m/z [M + H]⁺ 321.1197, found 321.1192.

N,N'-Sulfonyl-bis-[(4*S*)-isobutyl-oxazolidin-2-one] **2d**. Yield: 68%; mp 112–114°C; $R_f = 0.71$ (CH₂Cl₂: MeOH 95:5). $[\alpha]_D = +117.4$ ($c = 1$, CH₂Cl₂). ¹H NMR (CDCl₃, δ): 4.55–4.30 (2dd, $J = 3.8, 8.6, 6.2$ Hz, 4H), 4.50 (m, 2H), 2.1 (m, 2H), 1.65 (m, 4H), 1.05 (2d, $J = 9.2$ Hz, 12H). ¹³C NMR (CDCl₃, δ) 152.7, 68.2, 59.4, 41.2, 24.3, 23.1, 21.8. IR (KBr, ν): 1794, 1405, 1189 cm⁻¹. MS ESI⁺ 30 eV m/z : 371 [M +

Na]⁺. HRMS calcd for C₁₄H₂₄N₂O₆S + H⁺: m/z [M + H]⁺ 349.0264, found 349.0259.

N,N'-Sulfonyl-bis-[(4*S*)-benzyl-oxazolidin-2-one] **2e**. Yield = 72%; mp 125–127°C; $R_f = 0.77$ (CH₂Cl₂: MeOH 95:5). $[\alpha]_D = -34.5$ ($c = 1$, CH₂Cl₂). ¹H NMR (CDCl₃, δ): 7.40 (m, 10H), 4.87 (m, 2H); 4.61–4.25 (2dd, $J_{vc} = 3.9, 8.7, 9.2$ Hz, 4H); 3.68–3.00 (2dd, $J_c = 3.7, 9.1, 13.6$ Hz, 4H). ¹³C NMR (CDCl₃, δ): 154.7, 136.4, 135.3, 131.4, 128.4, 127.5, 126.7, 68.2, 60.1, 41.2. IR (KBr, ν): 1782, 1392, 1175 cm⁻¹. MS ESI⁺ 30 eV m/z : 439 [M + Na]⁺. HRMS calcd for C₂₀H₂₂N₂O₆S + H⁺: m/z [M + H]⁺ 417.0135, found 417.0143.

N,N'-Sulfonyl-4*S*-isopropyl,4'*S*-isobutyl-bis-oxazolidin-2-one **3**. Yield = 65%; mp 100–102°C; ¹H NMR (CDCl₃, δ): 4.60 (m, 1H); 4.05–4.35 (m, 4H); 3.70 (m, 1H); 1.70 (m, 2H); 1.55 (m, 2H); 1.00 (2d, $J = 6.7$ Hz, 6H); 0.90 (d, $J = 6.9$ Hz, 6H). ¹³C NMR (CDCl₃, δ): 160.2, 156.3, 68.4, 66.8, 58, 56, 41.8, 31.9, 25.1, 23.2, 21.1, 18.1, 17.2. MS ESI⁺ 30 eV m/z : 385 [M + Na]⁺. HRMS calcd for C₁₃H₂₂N₂O₆S + H⁺: m/z [M + H]⁺ 438.9784, found 438.9779.

ACKNOWLEDGMENTS

Fruitful discussions with Mrs. Mesbahi Hadjira are greatly appreciated (Faculty of Science).

REFERENCES

- [1] Bowerscock, T. L.; Salmon, S. A.; Portis, E. S.; Prescott, J. F.; Robinson, D. A.; Ford, C. W.; Watts, J. L. *Antimicrob Agents Chemother* 2004, 44, 1367.
- [2] Skold, O. *Acta Vert Scand* 2000, 23.
- [3] Johnson, A. P.; Warner, M.; Livermore, D. M. *J Antimicrob Chemother* 2000, 45, 953.
- [4] Philips, O. A.; Udo, E. E.; Ali, A. A.; Al-Hassawi, N. *Bioorg Med Chem* 2002, 10, 1.
- [5] Ciske, F. L.; Barbachyn, M. R.; Genin, M. J.; Grega, K. C.; Lee, C. S.; Dolak, L. A. Seest, E. P.; Watt, W.; Adams, W. J.; Friis, M. J.; Ford, C. W.; Zurenko, G. E. *Bioorg Med Chem Lett* 2003, 13(23), 4235.
- [6] Cynamon, M. H.; Klemens, S. P.; Sharpe, C. A. *Antimicrob Agents Chemother* 1999, 43, 1189.
- [7] Ager, J. A.; Prakach, I.; Schaad, D. R. *Aldrichim Acta* 1997, 30, 3–12.
- [8] Ager, J. A.; Prakach, I.; Schaad, D. R. *Chem Rev* 1996, 96, 835.
- [9] Evans, D. A. *Aldrichim Acta* 1982, 15, 23.
- [10] Evans, D. A.; Dow, R. L. *Tetrahedron Lett* 1986, 27, 1007.
- [11] Wu, Y.; Shen, X. *Tetrahedron: Asymmetry* 2000, 11, 1455.
- [12] Barta, S. J.; Silder, D. R.; Somerville, K. B.; Weissman, S. A.; Larsen, R. D.; Reider, P. J. *J Org Chem* 2000, 2, 2821.
- [13] Katz, S. J.; Bergmeier, S. C. *Tetrahedron Lett* 2002, 43, 557.

- [14] Park, C. S.; Kim, M. S.; Sim, T. B.; Pyun, D. K.; Lee, C. H.; Choi, D.; Lee, W. K. *J Org Chem* 2003, 68, 43.
- [15] Sim, T. B.; Kang, S. H.; Lee, K. S.; Lee, W. K. *J Org Chem* 2003, 68, 104.
- [16] Dewynter, G.; Abdaoui, M.; Toupet, L.; Montero, J.-L. *Tetrahedron Lett* 1997, 38, 8691.
- [17] Lee, S. G.; Lin, C. W.; Kim, D. C.; Lee, J. K. *Tetrahedron: Asymmetry* 2000, 11, 1455.
- [18] Berredjem, M.; Winum, J.-Y.; Toupet, L. Masmoudi, O.; Aouf, N.; Montero, J.-L. *Synthetic Commun* 2004, 34, 1653.
- [19] Paquette, L. (Ed.). *Encyclopedia of Reagents for Organic Synthesis*; Wiley: Chichester, UK, 1995; BOP-Cl, Vol. 1, p. 543; CDI, Vol. 2, p. 1006; sulfuryl diimidazole, Vol. 7, p. 4709.
- [20] Gage, J. R.; Evans, D. A. *Org Synth* 1990, 68, 77.